{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021600","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.274567+00:00","generated_at":"2026-06-22T09:45:57.223531+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Graphite Bio announces two abstracts accepted for ASH 2022 annual meeting","bullets":["Abstract #5965 describes beta-globin gene replacement strategy for beta-thalassemia using UltraHDR platform.","Abstract #3468 (poster) details single-cell RNA sequencing method to assess gene-editing outcomes in sickle cell disease.","CEO Josh Lehrer notes initial proof-of-concept data for nula-cel (SCD therapy) expected mid-2023.","Nula-cel is a first-in-human gene correction therapy; FDA granted Fast Track and Orphan Drug designations.","ASH meeting takes place Dec 10-13, 2022 in New Orleans."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021600","json":"https://secwatch.observer/filing/0000950170-22-021600.json","markdown":"https://secwatch.observer/filing/0000950170-22-021600.md","text":"https://secwatch.observer/filing/0000950170-22-021600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000095017022021600/0000950170-22-021600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000095017022021600/grph-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:45:57.223531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}